Item
1.01
|
Entry into a
Material Definitive Agreement.
|
Securities
Purchase Agreement
On March 30, 2020, Propanc Biopharma,
Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities
Purchase Agreement”) whereby an investor (the “Investor”) purchased from the Company, 7,500,000 units (the “Units”),
each consisting of (i) 1.5 shares of the Company’s common stock (the “Common Stock”), or pre-funded warrants
(the “Prefunded Warrants”) and (ii) 1.5 warrants to purchase one share of Common Stock (“Series A Warrants”,
and collectively with the Common Stock the “Units”). In addition to the Units, the Investor was issued 63,750,000
warrants to purchase one share of Common Stock (the “Series B Warrants”) and an additional 63,750,000 warrants to
purchase one share of Common Stock, subject to a vesting schedule (the “Series C Warrants” and, together with the
Prefunded Warrants, the Series A Warrants, and the Series B Warrants, the “Warrants”). The aggregate purchase price
for the Units, the Series A Warrants, the Series B Warrants and the Series C Warrants of $450,000 was paid at closing (the “Purchase
Price”). The 11,250,000 shares of Common Stock underlying the Units issuable at closing of the Securities Purchase Agreement
are comprised of 804,518 shares of restricted Common Stock and 10,445,482 Prefunded Warrants.
The
Securities Purchase Agreement contains such representations, warranties and covenants as are typical for a transaction of this
nature.
Series
A Warrants
Pursuant
to the Securities Purchase Agreement, the Investor purchased Series A Warrants to purchase up to 11,250,000 shares of Common Stock,
subject to adjustment as provided therein. The Series A Warrants have a cash exercise price of $0.20 per share. The Series A Warrants
contain a provision for cashless exercise in the event there is no effective registration statement registering the shares underlying
the Series A Warrants calculated based on the difference between the exercise price of the Series A Warrant and the trading price
of the stock (the “Cashless Exercise”).Additionally, the Series A Warrants contain a provision for a cashless conversion
at the Holder’s option should the trading price of the Common Stock fall below $0.20 per share calculated based on the difference
between the exercise price of the Series A Warrant and 70% of the Market Price, as defined therein (the” Alternate Cashless
Exercise”).
Series
B Warrants
Pursuant
to the Securities Purchase Agreement, the Investor purchased Series B Warrants to purchase up to 63,750,000 shares of Common Stock,
subject to adjustment as provided therein; provided, however, commencing on the 90th day following the effective date, the Company
may reduce the number of Warrant Shares issuable upon exercise thereof by 37,500,000 upon 10 Trading Days’ prior written
notice to the Holder provided that the Company issues to the Holder 3,750,000 shares of Common Stock (or, at the election of the
Holder, an equivalent number of pre-funded warrants) and Series A Warrants to purchase up to 3,750,000 shares of Common Stock,
which shares shall be issued pursuant to a registration statement without restrictions on resale. The Series B Warrants have a
cash exercise price of $0.04 per share. The Series B Warrants contain a provision for Cashless Exercise.
Series
C Warrants
Pursuant
to the Securities Purchase Agreement, the Investor purchased Series C Warrants to purchase up to 63,750,000 shares of Common Stock,
subject to adjustment as provided therein. The Series C Warrants have a cash exercise price of $0.20 per share, subject to the
vesting schedule set forth therein, which is based on such Holder’s exercise of the Series B Warrants. The Series C Warrants
contain provisions for Cashless Exercise and Alternate Cashless Exercise.
Registration
Rights Agreement
In
connection with the Securities Purchase Agreement, the Company and the Investor entered into a registration rights agreement (the
“Registration Rights Agreement”) pursuant to which the Company agreed to register the shares of Common Stock underlying
the Securities Purchase Agreement. The Registration Rights Agreement provides that the Company shall (i) use its best efforts
to file with the Commission the Registration Statement within 60 days of the date of the Registration Rights Agreement; and (ii)
have the Registration Statement declared effective by the Commission within 90 days of the date of the Registration Rights Agreement,
or within 120 days of the date of the Registration Rights Agreement in the event of a full review by the Commission. The Registration
Rights Agreement also provides that in the event of a limited or no review by the Commission, the Company shall use its best efforts
to have the Registration Statement declared effective on the earlier of (i) the 90th day from the date of the Registration
Rights Agreement or (ii) the fifth trading date following the Company’s receipt of notice from the Commission that the Registration
Statement will not be reviewed or is no longer subject to further review and comments.
The
foregoing provides only brief descriptions of the material terms of the Securities Purchase Agreement, the Registration Rights
Agreement and the Warrants, and does not purport to be a complete description of the rights and obligations of the parties thereunder,
and such descriptions are qualified in their entirety by reference to the full text of the forms of Securities Purchase Agreement,
Registration Rights Agreement and the Warrants, respectively, filed as exhibits to this Current Report on Form 8-K, and are incorporated
herein by reference.